Selective accumulation of hybrid liposomes into adult T-cell leukemia cells along with induction of apoptosis

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 13, 2011, Pages 3962-3965

  Komizu, Yuji ^a   Yukihara, Mamiko ^a   Kariya, Ryusho ^b   Goto, Koichi ^a   Okada, Seiji ^b   Ueoka, Ryuichi ^a  

^a SOJO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Adult T cell leukemia cell; Apoptosis; Hybrid liposomes; Membrane fluidity

Indexed keywords

CASPASE 3; DIMYRISTOYLPHOSPHATIDYLCHOLINE; HYBRID LIPOSOME; LIPOSOME; POLIDOCANOL; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG INHIBITION; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; T CELL LEUKEMIA;

APOPTOSIS; CARMUSTINE; CELLS, CULTURED; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DRUG DELIVERY SYSTEMS; HEXOSES; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LIPOSOMES; POLYSORBATES;

EID: 79958755326     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.05.015     Document Type: Article

References (25)

1. Poiesz, B. J.; Ruscetti, F. W.; Gazdar, A. F.; Bunn, P. A.; Minna, J. D.; Gallo, R. C. Proc. Natl. Acad. Sci. U. S. A. 1980, 77, 741.
2. Hinuma, Y.; Nagata, K.; Hanaoka, H.; Nakai, M.; Matsumoto, T.; Kinoshita, K.; Shirakawa, S.; Miyoshi, I. Proc. Natl. Acad. Sci. U. S. A. 1981, 78, 6476.
3. Brauweiler, A.; Garrus, J. E.; Reed, J. C.; Nyborg, J. K. Virology 1997, 231, 135.
4. Maeda, T.; Yamada, Y.; Moriuchi, R.; Sugahara, K.; Tsuruda, K.; Joh, T.; Atogami, S.; Tsukasaki, K.; Tomonaga, M.; Kamihira, S. J. Exp. Med. 1999, 189, 1063.
5. Matsuda, T.; Almasan, A.; Tomita, M.; Uchihara, J.-N.; Masuda, M.; Ohshiro, K.; Takasu, N.; Yagita, H.; Ohta, T.; Mori, N. J. Virol. 2005, 79, 1367.
6. Kuwazuru, Y.; Hanada, S.; Furukawa, T.; Yoshimura, A.; Sumizawa, T.; Utsunomiya, A.; Ishibashi, K.; Saito, T.; Uozumi, K.; Maruyama, M. Blood 1990, 76, 2065.
7. Taylor, J. M.; Nicot, C. Apoptosis 2008, 13, 733.
8. Ueoka, R.; Matsumoto, Y.; Moss, R. A.; Swarup, S.; Sugii, A.; Harada, K.; Kikuchi, J.; Murakami, Y. J. Am. Chem. Soc. 1988, 110, 1588.
9. Kitamura, I.; Kochi, M.; Matsumoto, Y.; Ueoka, R.; Kuratsu, J.; Ushio, Y. Cancer Res. 1996, 56, 3986.
10. Matsumoto, Y.; Iwamoto, Y.; Matsushita, T.; Ueoka, R. Int. J. Cancer 2005, 115, 377.
11. Ichihara, H.; Funamoto, K.; Matsushita, T.; Matsumoto, Y.; Ueoka, R. Int. J. Pharm. 2010, 394, 174.
12. Ichihara, H.; Nagami, H.; Kiyokawa, T.; Matsumoto, Y.; Ueoka, R. Anticancer Res. 2008, 28, 1187.
13. Huang, S. K.; Lee, K. D.; Hong, K.; Friend, D. S.; Papahadjopoulos, D. Cancer Res. 1992, 52, 5135.
14. Nagami, H.; Matsumoto, Y.; Ueoka, R. Int. J. Pharm. 2006, 315, 167.
15. Miyoshi, I.; Kubonishi, I.; Yoshimoto, S.; Akagi, T.; Ohtsuki, Y.; Shiraishi, Y.; Nagata, K.; Hinuma, Y. Nature 1981, 294, 770.
16. Yamamoto, N.; Okada, M.; Koyanagi, Y.; Kannagi, M.; Hinuma, Y. Science 1982, 217, 737.
17. Nakano, K.; Iwamoto, Y.; Takata, W.; Matsumoto, Y.; Ueoka, R. Bioorg. Med. Chem. Lett. 2002, 12, 3251.
18. Towata, T.; Komizu, Y.; Suzu, S.; Ueoka, R.; Okada, S. Biochem. Biophys. Res. Commun. 2010, 393, 445.
19. Komizu, Y.; Matsumoto, Y.; Ueoka, R. Bioorg. Med. Chem. Lett. 2006, 16, 131.
20. Yukihara, M.; Komizu, Y.; Tanoue, O.; Matsushita, T.; Matsumoto, Y.; Ueoka, R. Yakugaku Zasshi 2010, 130, 1581.
21. Komizu, Y.; Nakata, S.; Goto, K.; Matsumoto, Y.; Ueoka, R. ACS Med. Chem. Lett. 2011, 2, 275.
22. Nicoletti, I.; Migliorati, G.; Pagliacci, M. C.; Grignani, F.; Riccardi, C. J. Immunol. Methods 1991, 139, 271.
23. Komoriya, A.; Packard, B. Z.; Brown, M. J.; Wu, M. L.; Henkart, P. A. J. Exp. Med. 2000, 191, 1819.
24. 2, 10 mM KCl, 0.1% NP-40, 0.5 mM DTT, 0.5 mM PMSF, 2 μg/ml pepstatin A, 2 μg/ml aprotinin and 2 μg/ml leupeptin). After the incubation on ice for 10 min, the samples were vortexed for 10 s and centrifuged at 5000 rpm for 1 min. Then the supernatant was collected as a cytoplasmic sample. Then the cytoplasmic protein (40 μg protein) was separated by 12% SDS-PAGE and blotted onto a PVDF membrane (GE Healthcare, Tokyo, Japan). The detection was performed using ECL Plus Western Blotting Detection System (ECL, GE Healthcare Bio-Science, Buckinghamshire, UK). Primary antibodies used were as follows: anti-Caspase3 (#9661S) (Cell Signaling Technology, Danvers, MA, USA) and anti-Actin (C-2)(Santa Cruz Biotechnology, Santa Cruz, CA, USA). Second antibody used was ECL anti-rabbit IgG Horse Radish Peroxidase linked whole antibody (GE Healthcare Bio-Science, Buckinghamshire, UK).
25. Seubwai, W.; Vaeteewoottacharn, K.; Hiyoshi, M.; Suzu, S.; Puapairoj, A.; Wongkham, C.; Okada, S.; Wongkham, S. Cancer Sci. 2010, 101, 1590.